Looking Into Epizyme’s Return On Capital Employed
According to Benzinga Pro data, during Q2, Epizyme (NASDAQ:EPZM) posted sales of $27.53 million. Earnings were up 35.6%, but Epizyme still reported an overall loss of $35.74 million.
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
